Bank of Montreal Can raised its position in shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Free Report) by 8.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,787,655 shares of the real estate investment trust's stock after buying an additional 211,686 shares during the quarter. Bank of Montreal Can owned about 1.12% of Sabra Healthcare REIT worth $51,962,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in the company. Covestor Ltd grew its position in shares of Sabra Healthcare REIT by 23,720.0% during the third quarter. Covestor Ltd now owns 2,382 shares of the real estate investment trust's stock worth $45,000 after acquiring an additional 2,372 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Sabra Healthcare REIT by 150.7% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,555 shares of the real estate investment trust's stock valued at $47,000 after purchasing an additional 1,536 shares during the period. Farther Finance Advisors LLC grew its position in Sabra Healthcare REIT by 685.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,952 shares of the real estate investment trust's stock worth $74,000 after purchasing an additional 3,449 shares during the last quarter. Hantz Financial Services Inc. grew its position in Sabra Healthcare REIT by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,956 shares of the real estate investment trust's stock worth $74,000 after purchasing an additional 2,676 shares during the last quarter. Finally, Fifth Third Bancorp increased its stake in shares of Sabra Healthcare REIT by 20.5% in the third quarter. Fifth Third Bancorp now owns 4,675 shares of the real estate investment trust's stock valued at $87,000 after purchasing an additional 795 shares during the period. 99.40% of the stock is currently owned by institutional investors.
Sabra Healthcare REIT Price Performance
NASDAQ:SBRA opened at $20.78 on Friday. The company has a quick ratio of 4.29, a current ratio of 4.29 and a debt-to-equity ratio of 0.90. The business's 50-day moving average price is $19.62 and its 200 day moving average price is $19.00. Sabra Healthcare REIT, Inc. has a 52-week low of $15.75 and a 52-week high of $21.07. The firm has a market cap of $5.24 billion, a P/E ratio of 32.47, a PEG ratio of 1.66 and a beta of 0.64.
Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The real estate investment trust reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). The business had revenue of $201.35 million during the quarter, compared to analyst estimates of $201.97 million. Sabra Healthcare REIT had a net margin of 20.09% and a return on equity of 5.63%. Sabra Healthcare REIT's revenue was up 16.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.36 earnings per share. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. As a group, sell-side analysts predict that Sabra Healthcare REIT, Inc. will post 1.45 earnings per share for the current fiscal year.
Sabra Healthcare REIT Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Friday, February 13th were given a $0.30 dividend. The ex-dividend date was Friday, February 13th. This represents a $1.20 annualized dividend and a yield of 5.8%. Sabra Healthcare REIT's payout ratio is 187.50%.
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the company. Truist Financial increased their price objective on Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock a "hold" rating in a report on Tuesday, January 20th. UBS Group raised their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a "neutral" rating in a report on Thursday, February 19th. Wells Fargo & Company upped their price objective on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Tuesday, November 25th. Citizens Jmp raised their target price on shares of Sabra Healthcare REIT from $22.00 to $23.00 and gave the company a "market outperform" rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings restated a "buy (b)" rating on shares of Sabra Healthcare REIT in a research report on Thursday, January 22nd. Five research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $21.80.
Get Our Latest Stock Analysis on Sabra Healthcare REIT
Sabra Healthcare REIT Company Profile
(
Free Report)
Sabra Healthcare REIT, Inc NASDAQ: SBRA is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.
Serving a broad spectrum of care segments, Sabra's tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sabra Healthcare REIT, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sabra Healthcare REIT wasn't on the list.
While Sabra Healthcare REIT currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.